Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating its model to account for the company’s update this month that the Phase 3 CMV trial was not being stopped early for efficacy as well as Moderna’s revenue guidance revisions and bird flu vaccine headlines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna awarded tender for COVID-19 vaccine in EU, Norway and North Macedonia
- Moderna Secures EU Tender for mRNA COVID-19 Vaccine Supply
- Why I Don’t Believe Larry Ellison’s Moderna Stock Hype
- VOO ETF News, 1/23/2025
- Moderna (MRNA) Surges after Oracle’s Larry Ellison Praises AI-Driven Cancer Vaccines